AL
Alnylam Pharmaceuticals
ALNY · NASDAQ
$266.11 +3.13% (+$8.09)
1M +21.40%
Market Cap $35.4B
P/E Ratio 43.80x
Div. Yield -
ROE 93.61%
Bulios Fair Price
$181.34
31.9% downside
Trenutna cena
$266.11
Podcenjeno Poštena vrednost Precenjeno
Po podatkih Bulios Fair Price je delnica ALNY trenutno precenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Piotroski F-Score Moderate
6/9Valuation
1 /100
Expensive P/E 43.80x
EV/EBITDA 30.38x
P/FCF 65.23x
Growth
100 /100
Growing Rev. growth 52.98%
EPS growth N/A
FCF growth N/A
Profitability
86 /100
Strong Gross margin 79.72%
Net margin 16.82%
FCF margin 11.29%
Quality
96 /100
Excellent ROIC 25.65%
ROE 93.61%
Asset turnover 0.86x
Debt
75 /100
Low Debt/Equity 0.94x
Current ratio 3.05x
Net debt/EBITDA -0.38x
Stability
19 /100
Unstable Beta 0.28x
Rev. volatility 28.11%
Profitable years 1
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o ALNY
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Yvonne L. Greenstreet
Employees
2,500
Headquarters
Cambridge
Prihajajoči dogodki
29 OKT.
Earnings
Upcoming earnings report